Key takeaways
- An international study of 7 million patients found GLP-1 users are up to 51% less likely to develop active tuberculosis compared to those on older diabetes drugs.
- A Harvard-led study of 50,000 adults showed tirzepatide reduces infection-related deaths by 60% and infection hospitalizations by 36% over one year.
- Animal models suggest GLP-1s directly enhance immune cell function, specifically boosting neutrophil bacterial clearance and phagocytosis.
- These immune-boosting benefits add powerful clinical value for patients paying out-of-pocket for telehealth GLP-1 therapies.
What happened
New clinical data reveals that GLP-1 receptor agonists, such as semaglutide and tirzepatide, significantly reduce the risk of active tuberculosis and serious infection-related hospitalizations. According to two major real-world studies published in late August 2026, these metabolic therapies provide a powerful boost to the innate immune system that goes far beyond simple blood sugar control. The research shows that patients taking GLP-1 medications experience far fewer severe bacterial infections and lower infection-related mortality compared to those taking older, traditional diabetes drugs.
Why it matters
These findings represent a massive shift in how clinical researchers and US buyers view GLP-1 medications. Historically treated as lifestyle drugs for weight loss, medications like Wegovy and Zepbound are increasingly recognized as systemic anti-inflammatory and immunoprotective therapies.
For the millions of Americans living with type 2 diabetes or obesity, this data translates to tangible safety benefits. Both diabetes and obesity are known to impair the immune system, leaving patients highly vulnerable to severe infections. Obesity alone is estimated to play a role in one out of every ten infection-related deaths in adults, driven by chronic systemic inflammation and metabolic dysfunction. For telehealth buyers paying out-of-pocket for these medications, these added immunological protections provide powerful clinical justification for the high monthly cash cost of treatment.
What the data says
The clinical evidence comes from two distinct, large-scale studies. The first, an international cohort study of more than 7 million people with type 2 diabetes published in Nature Communications, evaluated the risk of developing active tuberculosis (TB). The researchers, led by Dr. Chih-Cheng Lai of Chi Mei Medical Center in Taiwan, compared GLP-1 users against patients taking other common diabetes medications.
The study found that GLP-1 patients were significantly less likely to develop active TB than those on other regimens:
- 51% less likely than those taking DPP-4 inhibitors (HR 0.49)
- 47% less likely than those taking sulfonylureas (HR 0.53)
- 40% less likely than those taking metformin (HR 0.60)
- 18% less likely than those taking SGLT2 inhibitors (HR 0.82)
The second study, published in The BMJ and led by Dr. Nils Krüger of Harvard Medical School, looked at more than 50,000 US adults with type 2 diabetes and established cardiovascular disease. This trial tracked patients taking the dual GLP-1/GIP agonist tirzepatide (the active ingredient in Mounjaro and Zepbound) against those taking sitagliptin, a DPP-4 inhibitor.
Over a one-year follow-up period, tirzepatide users demonstrated remarkably lower infection risks across multiple categories:
- Infection-related mortality: 60% reduction (HR 0.40)
- Infection-related hospitalization: 36% reduction (HR 0.64)
- Urinary tract infections (UTIs): 17% reduction (HR 0.83)
- Infections in any care setting: 17% reduction (HR 0.83)
To explain these results, researchers point to animal models. In diabetic mice fed a high-fat diet, GLP-1 receptor agonists outperformed insulin in restoring immune defenses. The drugs directly enhanced neutrophil phagocytosis (the process by which immune cells engulf and destroy bacteria), boosted bacterial clearance, and corrected the white blood cell counts damaged by chronic high blood sugar.
How it compares
Compared to standard diabetes medications like metformin, sulfonylureas, or DPP-4 inhibitors, GLP-1 therapies offer broad systemic advantages. Older medications successfully lower blood glucose, but they do not actively repair the immune cell dysfunction associated with metabolic disease.
In terms of cost, however, these classes are vastly different. While a month of metformin or sitagliptin can cost under $15 at a local pharmacy, brand-name GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound carry US retail prices ranging from $900 to $1,350 per month without insurance.
Because of these steep prices, many US patients bypass insurance hurdles by using online telehealth clinics. Through telehealth providers, patients can access compounded semaglutide and compounded tirzepatide, which generally range from $150 to $400 per month. On the CompareRx provider directory, buyers can compare various licensed telehealth platforms to find flat-rate pricing structures that make accessing these multi-benefit metabolic treatments more affordable.
How this fits the bigger picture
This new data fits perfectly into a rapidly growing body of medical literature showing that GLP-1s treat the entire body, not just a patient's weight. Over the last year, we have seen the clinical scope of these drugs expand to include heart, liver, kidney, and brain health.
For example, the FDA recently expanded Mounjaro's approved uses, as we outlined in our coverage of the FDA approving Mounjaro for cardiovascular risk reduction. Similarly, emerging studies have shown these therapies reduce systemic inflammation elsewhere, which we explored when analyzing how GLP-1s are linked to ulcerative colitis remission. This new infection data suggests that the reduction in all-cause mortality seen in GLP-1 cardiovascular trials is not just due to cleaner arteries, but also because patients' bodies are physically more capable of fighting off severe bacterial infections.
This multi-organ protection makes securing reliable, long-term access to therapy vital. As insurance companies continue to tighten restrictions on coverage, more patients are navigating the cash-pay landscape. Tools like our comprehensive telehealth comparison engine help patients weigh their clinical options, helping them maintain uninterrupted metabolic therapy and secure these newly discovered survival benefits.
What happens next
Clinical teams will continue to investigate how GLP-1s influence the human immune system. We can expect upcoming translational studies and clinical trials to examine whether these drugs can be used as temporary adjuvant therapies during severe infections, or if they can boost vaccine efficacy in patients with obesity and type 2 diabetes.
Meanwhile, the FDA is reviewing several supplemental drug applications from manufacturers Eli Lilly and Novo Nordisk to add new metabolic, cardiovascular, and renal benefits to their official US prescribing labels. As more data emerges, the pressure on insurance companies to cover these life-saving therapies will only intensify.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication regimen.